NASDAQ:COLL Collegium Pharmaceutical (COLL) Stock Price, News & Analysis → Controversial CEO explains new way to amass wealth (From Stansberry Research) (Ad) Free coll Stock Alerts $37.02 -0.49 (-1.31%) (As of 05/6/2024 ET) Add Compare Share Share Today's Range$36.88▼$37.9250-Day Range$34.74▼$40.9152-Week Range$20.83▼$40.95Volume304,924 shsAverage Volume419,604 shsMarket Capitalization$1.21 billionP/E Ratio31.37Dividend YieldN/APrice Target$39.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Collegium Pharmaceutical alerts: Email Address Collegium Pharmaceutical MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside5.3% Upside$39.00 Price TargetShort InterestBearish22.86% of Float Sold ShortDividend StrengthN/ASustainability-2.78Upright™ Environmental ScoreNews Sentiment0.42Based on 7 Articles This WeekInsider TradingN/AProj. Earnings Growth10.30%From $5.63 to $6.21 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.31 out of 5 starsMedical Sector489th out of 908 stocksPharmaceutical Preparations Industry220th out of 424 stocks 1.3 Analyst's Opinion Consensus RatingCollegium Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCollegium Pharmaceutical has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted22.86% of the float of Collegium Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverCollegium Pharmaceutical has a short interest ratio ("days to cover") of 17.3, which indicates bearish sentiment.Change versus previous monthShort interest in Collegium Pharmaceutical has recently decreased by 1.83%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCollegium Pharmaceutical does not currently pay a dividend.Dividend GrowthCollegium Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCollegium Pharmaceutical has received a 26.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Tapendatol" and "Oxycodone" products. See details.Environmental SustainabilityThe Environmental Impact score for Collegium Pharmaceutical is -2.78. Previous Next 2.5 News and Social Media Coverage News SentimentCollegium Pharmaceutical has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Collegium Pharmaceutical this week, compared to 3 articles on an average week.Search Interest3 people have searched for COLL on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Collegium Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Collegium Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.98% of the stock of Collegium Pharmaceutical is held by insiders. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Collegium Pharmaceutical are expected to grow by 10.30% in the coming year, from $5.63 to $6.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Collegium Pharmaceutical is 31.37, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.96.Price to Earnings Ratio vs. SectorThe P/E ratio of Collegium Pharmaceutical is 31.37, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 157.50.Price to Book Value per Share RatioCollegium Pharmaceutical has a P/B Ratio of 6.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchDo NOT read if you believe in “woke” politicsI have to warn you, however: This CEO of a publicly traded company is not afraid to mince words. Many on Wall Street have refused to work with him.Everything you need to know is posted on our website here. About Collegium Pharmaceutical Stock (NASDAQ:COLL)Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Read More COLL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COLL Stock News HeadlinesMay 3, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Jazz Pharmaceuticals (JAZZ) and KalVista Pharmaceuticals (KALV)May 2, 2024 | americanbankingnews.comCollegium Pharmaceutical (NASDAQ:COLL) Downgraded by StockNews.com to BuyMay 7, 2024 | Stansberry Research (Ad)Do NOT read if you believe in “woke” politicsI have to warn you, however: This CEO of a publicly traded company is not afraid to mince words. Many on Wall Street have refused to work with him.May 2, 2024 | americanbankingnews.comCollegium Pharmaceutical (COLL) Scheduled to Post Quarterly Earnings on ThursdayMay 1, 2024 | stocknews.com3 Popular Pharma Stocks Worth Buying NowMay 1, 2024 | finance.yahoo.comAvalyn Bolsters Leadership Team with the Appointment of Douglas Carlson as Chief Financial Officer and Chief Business OfficerApril 29, 2024 | msn.comCollegium enters authorized generic agreement with Hikma for Nucynta franchiseApril 29, 2024 | finance.yahoo.comCollegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ERMay 7, 2024 | Stansberry Research (Ad)Do NOT read if you believe in “woke” politicsI have to warn you, however: This CEO of a publicly traded company is not afraid to mince words. Many on Wall Street have refused to work with him.April 25, 2024 | globenewswire.comCollegium to Report First Quarter 2024 Financial Results on May 9, 2024April 23, 2024 | money.usnews.comCollegium Pharmaceutical IncApril 12, 2024 | markets.businessinsider.comOptimistic Buy Rating for Collegium Pharmaceutical: Growth and Market Position AnalysisApril 11, 2024 | markets.businessinsider.comCritical Insights From Collegium Pharmaceutical Analyst Ratings: What You Need To KnowApril 11, 2024 | globenewswire.comCollegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026April 9, 2024 | finance.yahoo.comCollegium Pharmaceutical (COLL) Stock Sinks As Market Gains: What You Should KnowApril 4, 2024 | bizjournals.comNovan is gone. But its lead drug lives on with new companyApril 3, 2024 | markets.businessinsider.comLigand Pharmaceuticals Announces Launch Of Pelthos; Scott Plesha To Assume Leadership Of PelthosApril 3, 2024 | finance.yahoo.comCollegium to Participate in 23rd Annual Needham Virtual Healthcare ConferenceMarch 23, 2024 | wsj.comCollegium Pharmaceutical Inc.March 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for KalVista Pharmaceuticals on Strong Phase 3 Results and Solid Financial PositionMarch 5, 2024 | finance.yahoo.comCOLL Mar 2024 50.000 callMarch 4, 2024 | insidermonkey.com5 Best Small Cap Pharma Stocks to Invest InFebruary 29, 2024 | finance.yahoo.comInsider Sell: EVP & Chief Commercial Officer Scott Dreyer Sells 10,000 Shares of Collegium ...February 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Protagonist Therapeutics (PTGX) and Viridian Therapeutics (VRDN)February 27, 2024 | finance.yahoo.comThis Unsung Pharmaceutical Stock In The IBD 50 Hit A Buy Zone. Here's Why.February 26, 2024 | seekingalpha.comCollegium Pharmaceutical Q4: The Beat Goes OnFebruary 25, 2024 | msn.comNasdaq Closes In On All-Time High; Carvana Spikes On Earnings While Nvidia Vaults Above 800See More Headlines Receive COLL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today5/06/2024Next Earnings (Confirmed)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:COLL CUSIPN/A CIK1267565 Webwww.collegiumpharma.com Phone(781) 713-3699FaxN/AEmployees197Year FoundedN/APrice Target and Rating Average Stock Price Target$39.00 High Stock Price Target$40.00 Low Stock Price Target$37.00 Potential Upside/Downside+5.3%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$1.18 Trailing P/E Ratio31.37 Forward P/E Ratio6.58 P/E GrowthN/ANet Income$48.15 million Net Margins8.50% Pretax Margin13.36% Return on Equity107.39% Return on Assets17.07% Debt Debt-to-Equity Ratio2.48 Current Ratio1.17 Quick Ratio1.10 Sales & Book Value Annual Sales$566.77 million Price / Sales2.14 Cash Flow$10.64 per share Price / Cash Flow3.48 Book Value$5.99 per share Price / Book6.18Miscellaneous Outstanding Shares32,710,000Free Float31,404,000Market Cap$1.21 billion OptionableOptionable Beta1.06 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Michael Thomas Heffernan B.S. Pharm (Age 60)R.Ph., Co-Founder & Chairman Comp: $110kMr. Joseph J. Ciaffoni (Age 52)President, CEO & Director Comp: $1.69MMs. Colleen Tupper (Age 48)Executive VP & CFO Comp: $848.29kMs. Shirley R. Kuhlmann (Age 40)Executive VP, General Counsel, Chief Administrative Officer & Secretary Comp: $842.9kMr. Scott Dreyer (Age 52)Executive VP & Chief Commercial Officer Comp: $746.58kDr. Thomas B. Smith FAAFP (Age 63)M.D., Executive VP & Chief Medical Officer Comp: $692.91kDr. Christopher Shayne James M.D.Vice President of Investor RelationsMr. Bart J. DunnExecutive Vice President of Strategy & Corporate DevelopmentMr. Scott SudduthHead of Technical OperationsMore ExecutivesKey CompetitorsIronwood PharmaceuticalsNASDAQ:IRWDPacira BioSciencesNASDAQ:PCRXSpyre TherapeuticsNASDAQ:SYREGemini TherapeuticsNASDAQ:GMTXBelite BioNASDAQ:BLTEView All CompetitorsInsiders & InstitutionsLSV Asset ManagementBought 248,751 shares on 5/6/2024Ownership: 1.163%Texas Permanent School Fund CorpBought 369 shares on 5/6/2024Ownership: 0.087%Quantbot Technologies LPSold 484 shares on 5/6/2024Ownership: 0.029%Gallacher Capital Management LLCBought 5,756 shares on 5/6/2024Ownership: 0.018%Mutual of America Capital Management LLCSold 7,173 shares on 5/2/2024Ownership: 0.284%View All Insider TransactionsView All Institutional Transactions COLL Stock Analysis - Frequently Asked Questions Should I buy or sell Collegium Pharmaceutical stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" COLL shares. View COLL analyst ratings or view top-rated stocks. What is Collegium Pharmaceutical's stock price target for 2024? 5 Wall Street analysts have issued 1-year price objectives for Collegium Pharmaceutical's shares. Their COLL share price targets range from $37.00 to $40.00. On average, they anticipate the company's stock price to reach $39.00 in the next twelve months. This suggests a possible upside of 5.3% from the stock's current price. View analysts price targets for COLL or view top-rated stocks among Wall Street analysts. How have COLL shares performed in 2024? Collegium Pharmaceutical's stock was trading at $30.78 at the beginning of 2024. Since then, COLL stock has increased by 20.3% and is now trading at $37.02. View the best growth stocks for 2024 here. When is Collegium Pharmaceutical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our COLL earnings forecast. How can I listen to Collegium Pharmaceutical's earnings call? Collegium Pharmaceutical will be holding an earnings conference call on Thursday, May 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Collegium Pharmaceutical's earnings last quarter? Collegium Pharmaceutical, Inc. (NASDAQ:COLL) released its quarterly earnings results on Thursday, February, 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.20 by $0.25. The specialty pharmaceutical company earned $149.75 million during the quarter, compared to the consensus estimate of $147.66 million. Collegium Pharmaceutical had a net margin of 8.50% and a trailing twelve-month return on equity of 107.39%. What ETFs hold Collegium Pharmaceutical's stock? ETFs with the largest weight of Collegium Pharmaceutical (NASDAQ:COLL) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), ETC 6 Meridian Small Cap Equity ETF (SIXS), SPDR S&P Pharmaceuticals ETF (XPH), Invesco S&P SmallCap Health Care ETF (PSCH), Pacer US Small Cap Cash Cows 100 ETF (CALF), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH). What guidance has Collegium Pharmaceutical issued on next quarter's earnings? Collegium Pharmaceutical updated its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $580.0 million-$595.0 million, compared to the consensus revenue estimate of $583.5 million. What is Joseph Ciaffoni's approval rating as Collegium Pharmaceutical's CEO? 6 employees have rated Collegium Pharmaceutical Chief Executive Officer Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among the company's employees. What other stocks do shareholders of Collegium Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH). When did Collegium Pharmaceutical IPO? Collegium Pharmaceutical (COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers. Who are Collegium Pharmaceutical's major shareholders? Collegium Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional investors include Principal Financial Group Inc. (4.75%), LSV Asset Management (1.16%), Mutual of America Capital Management LLC (0.28%), Assenagon Asset Management S.A. (0.22%), Los Angeles Capital Management LLC (0.21%) and Allspring Global Investments Holdings LLC (0.14%). Insiders that own company stock include Colleen Tupper, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer and Shirley R Kuhlmann. View institutional ownership trends. How do I buy shares of Collegium Pharmaceutical? Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:COLL) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersBiden’s $374B Giveaway Into This SectorDTIAI “wealth window” is closing June 25thParadigm PressThe 2024 crypto bull run has already started — don’t get left behindInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldHe Is Giving Away BitcoinCrypto Swap ProfitsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
